Transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic valve stenosis, particularly in patients who are at high or intermediate surgical risk. Since its introduction in 2002, TAVR has evolved into a viable alternative to surgical aortic valve replacement (SAVR), showing comparable, and in some cases superior, outcomes in terms of survival, quality of life, and procedural safety. This review provides a comprehensive examination of the current state of TAVR, including indications, procedural advancements, patient outcomes, and future directions. Recent randomized trials comparing TAVR with SAVR in low-risk patients, advances in valve technology, and ongoing challenges are also discussed.